Organon & Co.
NYQ: OGNLive Quote
📈 ZcoreAI Score
Our AI model analyzes Organon & Co.'s price action across multiple timeframes using regression channels and statistical scoring.
Get OGN Z-Score →About Organon & Co.
Healthcare
Drug Manufacturers - General
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
📊 Fundamental Analysis
Organon & Co. demonstrates a profit margin of 3.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -5.3% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is 30.6%, which reflects exceptional capital efficiency.
At a current price of $8.83, OGN currently sits at the 42nd percentile of its 52-week range (Range: $5.69 - $13.24).
💰 Valuation Insight
OGN trades at a 50.9% discount (PE: 12.26), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
✅
Return on Equity
Excellent
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$2.30B
Trailing P/E
12.26
Forward P/E
2.37
Beta (5Y)
0.64
52W High
$13.24
52W Low
$5.69
Avg Volume
5.30M
Day High
Day Low